Novo Nordisk launches Wegovy tablets in Mexico as public formulary updates semaglutide entry

Novo Nordisk began distributing oral semaglutide 25 mg (Wegovy tablets) in Mexico’s private market on November 11, after COFEPRIS approval in August. The same day, an update to the national formulary that public institutions follow took effect, listing semaglutide for type 2 diabetes and weight management.

Two new blank boxes slide into empty slots on a long shelf already holding a row of identical containers, with tiny silhouettes standing below for scale.

OBESITY · MARKET ACCESS · NOVEMBER 13, 2026 · MEXICO

Novo Nordisk began distributing Wegovy tablets (oral semaglutide 25 mg) in Mexico on November 11, with availability to expand gradually over the coming weeks to an estimated 10,000 points of sale, including pharmacies, online providers and other authorized channels, according to a release from the company’s Mexican unit. The Federal Commission for the Protection against Sanitary Risks (COFEPRIS), Mexico’s health regulator, granted the product’s marketing authorization (registro sanitario) in August, making Mexico the first country in Latin America to authorize it, the company said.

The launch coincided with a change in the public sector. On November 10, the General Health Council (Consejo de Salubridad General) published in the Official Gazette (Diario Oficial de la Federación, DOF) an agreement updating the National Compendium of Health Supplies (Compendio Nacional de Insumos para la Salud), the catalog that public health institutions follow. The update, in force since November 11, lists semaglutide in injectable and oral forms with indications for type 2 diabetes and weight management.

~10,000

Points of sale Novo Nordisk expects Wegovy tablets to reach in Mexico in the coming weeks, after distribution began on November 11, per the company.

The private-market launch

COFEPRIS authorized oral semaglutide 25 mg to reduce excess body weight and maintain long-term weight reduction in adults with obesity, or with overweight and at least one weight-related comorbidity, and to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight, according to the company’s August announcement and Expansión. In the phase 3 OASIS 4 trial, adults taking the tablet lost about 17% of their body weight after 64 weeks, the company said.

Patricia Field, general manager of Novo Nordisk Mexico, put the company’s potential market at about 7.5 million patients, of whom fewer than 1% receive treatment, according to Expansión. She said the price will depend on the dose and the pharmacy and will be competitive and close to that of the injectable form, and that the company is in talks with the government to widen access to its treatments. Distribution will run largely through the major private pharmacy chains, Expansión reported.

The oral option enters a market of injectable GLP-1 treatments. Until now, semaglutide for weight management in Mexico was available only as a weekly injection, the company said. HealthSignals has covered the oral GLP-1 pipeline and public payers’ moves on coverage elsewhere in the region, including Costa Rica’s Social Security Fund (CCSS).

What the formulary update does, and does not do

The agreement modifies the semaglutide entry in the compendium’s endocrinology and metabolism group, rather than adding the molecule for the first time, according to N+ and Consultor Salud; several outlets described it as an inclusion. The entry lists injectable pens for type 2 diabetes and three pens for weight management (0.68, 2.27 and 3.2 mg/mL) in adults with a body mass index (BMI) of 30 or more, or of 27 to under 30 with at least one weight-related comorbidity, and in adolescents over 12 with obesity and body weight above 60 kg, with a maintenance dose of 2.4 mg once a week. The oral presentations listed (tablets of 1.5, 3, 4, 7, 9 and 14 mg) are indicated for type 2 diabetes. The codes reported from the entry do not include a 25 mg tablet for weight management.

A listing in the compendium allows institutions such as the Mexican Social Security Institute (IMSS), the Institute for Social Security and Services for State Workers (ISSSTE) and IMSS-Bienestar to request the drug, but it is not an order to buy or distribute it, Infobae reported. Each institution must include it in its requirements, secure budget, run procurement and set prescribing rules. The agreement sets no purchase volumes, budget or supply timetable, according to Consultor Salud. The listing refers to the active ingredient, not a brand, Infobae noted.

The update was approved at the compendium commission’s eighth ordinary session on October 14 and signed on October 30 by Patricia Elena Clark Peralta, secretary of the General Health Council, according to N+. The same agreement adds iptacopan and tucatinib to the compendium, N+ and Consultor Salud reported.

What to Watch

  1. Retail prices for Wegovy tablets as distribution expands across pharmacy chains
  2. Whether IMSS, ISSSTE or IMSS-Bienestar include semaglutide for weight management in their purchase requirements
  3. Any request to add the 25 mg tablet to the national compendium

Why this is relevant

Patients

An oral weight-management option is now sold in Mexican pharmacies, paid out of pocket; public-sector access still depends on institutional purchases.

Industry

Novo Nordisk is first to market with an oral semaglutide for weight management in Latin America, and the compendium entry gives public institutions a basis to request semaglutide by active ingredient rather than brand.

Payers

The compendium entry lists semaglutide for weight management, but the agreement sets no purchase volumes, budget or supply timetable.

THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

Sources: DOF: Acuerdo por el que se actualiza el Compendio Nacional de Insumos para la Salud versión 2025 (November 10, 2026) · Novo Nordisk Mexico: Semaglutida oral 25 mg (Wegovy tabletas) llega a México (November 11, 2026) · Novo Nordisk Mexico via Infobae: Novo Nordisk obtiene en México la primera aprobación en América Latina para semaglutida oral 25 mg · Expansión: México aprueba las tabletas Wegovy de Novo Nordisk · Expansión: Novo Nordisk amplía su negocio contra la obesidad con Wegovy en tabletas · N+: Catálogo de Salud incluye semaglutida · Consultor Salud: México actualiza el Compendio Nacional de Insumos para la Salud · Infobae: Semaglutida entra al sector público; IMSS e ISSSTE podrán solicitarla · La Jornada: Salud incluye activo de Ozempic en su catálogo para tratar diabetes y obesidad

THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related